ArticleRSC advances2025
Dual surface functionalised curcumin-shellac nano-delivery system with enhanced antimicrobial action.
Article in RSC advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Curcumin-based nanotherapeutics for colibacillosis in chickens: advances in veterinary microbiology.Veterinary research communications · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We report a strong boost of the antimicrobial action of curcumin (CUR) upon encapsulation in sterically stabilized shellac-based nanoparticles (NPs) with cationic surface functionalisation. The CUR-loaded shellac NPs were fabricated by solvent attrition and co-precipitation by mixing an aqueous solution of ammonium shellac and an ethanolic solution of curcumin followed by a pH drop from 8 to 5 in the presence of the sterically stabilising polymer Poloxamer 407 (P407). The surface functionalisation of the produced curcumin nanocarrier was done by subsequent doping with the water-insoluble cationic surfactant octadecylthrimethylammonium bromide (ODTAB). Optimal nanocarrier stability was obtained at a fixed ratio of (0.25 : 0.2) wt% of shellac : poloxamer 407 concentrations. Shellac NP formulations containing 0.01-0.07 wt% concentration range of encapsulated CUR with 0.25 wt% shellac at pH 5 were successfully produced and examined for the efficiency of CUR encapsulation and its release from these nanocarriers. We studied the antibacterial action of CUR-NPs before and after the cationic surface functionalisation to evaluate the encapsulation efficiency, the role of the nanocarrier components and surface properties on its antibacterial, antiyeast and antialgal action. The antimicrobial effect of the surface functionalised CUR loaded-shellac NPs was evaluated on different proxy microorganisms, including
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.